Meeting time and cost challenges to accelerate drug development addressed in Inaugural MassBio symposium

Sponsored by PCI, event showcased the strong Massachusetts life science presence of CRO's and CMO's.

Posted: March 14, 2012

API Manufacturing and Pharmaceutical Manufacturing

Sponsored by PCI, event showcased the strong Massachusetts life science presence of contract research and contract manufacturing organizations

The inaugural Massachusetts Biotechnology Council (MassBio) CRM/CMO Symposium was a resounding success, according to Ed Price, President of PCI Synthesis and co-chair of MassBio’s new Massachusetts CRO/CMO Committee.  The one-day event held last week showcased the strong Massachusetts life science industry, particularly the contract research and contract manufacturing organizations that support small and large developers of new therapeutics.

“The symposium’s attendance was 30 percent higher than originally planned – testimony to not only the interest in networking and sharing best practices among CRO/CMO organizations, but also to the overall strength of the life science cluster here in the Commonwealth,” Price said.

Cost and time are the two main challenges life science companies face today, so the theme of the event – Accelerating Drug Development — was timely. The symposium gave attendees exposure to best practices in accelerating time-to-market strategies by leveraging Boston-based expertise. The Greater Boston area has seen tremendous growth in its local contract research and contract manufacturing organizations, which can assist any size life science firm with innovative technical solutions from drug discovery through clinical trials and commercial manufacturing.

Presentations were made by luminaries such as Josef H. von Rickenbach, Chair of the Board, CEO and Founder of PAREXEL International; Karen N. Archdeacon, Compliance Officer, FDA New England District; and Tim Murray, Lieutenant Governor of Massachusetts. Case studies, panel discussions and networking sessions rounded out the day, along with an exhibition area that featured more than 30 Boston-based researchers, suppliers and technical solution providers.

Scott H. Gillis, CEO, OnSite Therapeutics, Inc. and a member of the MassBio board, gave the closing remarks: “Events like this symposium advance the Bay State’s life sciences center of excellence, create new networks and partnerships, foster innovation and spur economic growth — all invaluable as we move forward in 2012.”

About PCI Synthesis

PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities, please visit www.pcisynthesis.com.

 

Contact:
Margaret Bonilla
Birnbach Communications
603-548-0693
mbonilla@birnbachcom.com

Related posts:

PCI wins top regulatory award –what that mean for you
PCI Synthesis’ sponsorship of NE CRO/CMO council aims to boost region’s life sciences cluster
PCI Synthesis Announces 8th Successful FDA Inspection
PCI Synthesis’ Ed Price Joins SOCMA’s Board of Governors
PCI Synthesis Submits Patent for Synthesizing Azelaic Acid

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.